drugset / Trial / NCT00641225
Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of single doses of SBI-087 in subjects with rheumatoid arthritis.
Timeline
- Start
- 2008-03-31
- Primary completion
- 2011-03-31
- Completion
- 2011-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SBI-087 | Protein / enzyme biologic | 0.015 mg/kg | Intravenous |
| Subject | SBI-087 | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Subject | SBI-087 | Protein / enzyme biologic | 50 mg | Intravenous |
| Subject | SBI-087 | Protein / enzyme biologic | 300 mg | Intravenous |